What is Wedbush’s Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Analysts at Wedbush issued their Q1 2025 EPS estimates for Wave Life Sciences in a research note issued on Tuesday, April 8th. Wedbush analyst Y. Zhong expects that the company will post earnings per share of ($0.27) for the quarter. Wedbush has a “Outperform” rating and a $18.00 price objective on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.04) EPS and FY2026 earnings at ($1.14) EPS.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million.

A number of other research analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, March 26th. StockNews.com raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Finally, Jefferies Financial Group started coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.18.

Wave Life Sciences Price Performance

Shares of NASDAQ WVE opened at $5.65 on Friday. The stock has a market capitalization of $867.20 million, a P/E ratio of -5.09 and a beta of -0.93. Wave Life Sciences has a 1 year low of $4.25 and a 1 year high of $16.74. The company has a 50-day moving average price of $9.44 and a 200-day moving average price of $11.66.

Insider Activity at Wave Life Sciences

In other news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the transaction, the chief executive officer now owns 338,351 shares in the company, valued at $3,238,019.07. This trade represents a 33.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the sale, the director now directly owns 16,115 shares in the company, valued at approximately $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Wave Life Sciences

Several large investors have recently made changes to their positions in WVE. GF Fund Management CO. LTD. bought a new position in Wave Life Sciences during the 4th quarter valued at approximately $40,000. Quarry LP bought a new position in shares of Wave Life Sciences during the fourth quarter valued at $62,000. KBC Group NV bought a new position in shares of Wave Life Sciences during the fourth quarter valued at $67,000. Summit Investment Advisors Inc. raised its position in shares of Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after purchasing an additional 2,308 shares during the last quarter. Finally, Westwood Wealth Management bought a new position in Wave Life Sciences in the 4th quarter worth about $124,000. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.